A study of the once-weekly investigational dipeptidyl peptidase-4 omarigliptin reported a clinically meaningful reduction in glycated hemoglobin that was maintained throughout the study.
Higher magnesium intake was linked to a 15% lower risk for type 2 diabetes.
Overall reduction in HbA1c was higher in people with T2D vs those with T1D.
New monitoring system involves the placement of a small sensor wire beneath the skin surface to continuously monitor glucose levels.
Researchers examined the efficacy of lifestyle intervention on glycemic control in type 2 diabetes.
GlaxoSmithKline expects Tanzeum supplies to be depleted by July 2018.
Approval for the new indication follows a review of the results of the LEADER trial.
Sodium-glucose cotransporter 2 inhibitors reduced both systolic and diastolic blood pressure in patients with type 2 diabetes.
One hundred fifteen patients used the FreeStyle Libre Pro sensor to monitor interstitial fluid glucose for 14 days.
A randomized double-blind trial examined the safety and efficacy of ertugliflozin plus metformin for inadequately controlled type 2 diabetes.
Canagliflozin reduced levels of cardiovascular stress biomarkers N-terminal pro-B type natriuretic peptide and high sensitivity troponin I.
Patients with type 2 diabetes had lower rates of heart failure hospitalization, MACE, and all-cause mortality when treated with dapagliflozin.
No between-group differences for factors such as glycemic control, endogenous glucose production, and insulin sensitivity were found.
Results of 2 large clinical trials confirmed previous safety concerns surrounding canagliflozin therapy for type 2 diabetes.
The combined treatment regimen of metformin and liraglutide led to complete remission in 74% of patients with new onset type 2 diabetes.
Early initiation of insulin therapy in patients with type 2 diabetes improved HbA1c, fasting blood sugar, postprandial blood sugar, and BMI.
Researchers examined 24-hour and ambulatory blood pressure to determine the relationship between hypertension and low levels of vitamin D.
A comprehensive systematic review analyzes whether specific sodium-glucose cotransporter 2 inhibitors were more likely to be associated with adverse renal events in patients with type 2 diabetes.
A cohort study of primary care records in the United Kingdom did not find an increased risk of major cardiovascular events in patients with type 2 diabetes treated with insulin.
Researchers found that those at risk for low vitamin B12 levels are often not properly monitored.
Endocrinology Advisor Articles
- ACP Defends Higher Blood Glucose Targets for Type 2 Diabetes
- Updated Clinical Practice Guidelines on Testosterone Therapy in Men With Hypogonadism
- Semaglutide May Be Useful for Treating Obesity in People Without Diabetes
- Once-Daily Oral Contraceptive for Men Shows Promise
- HbA1c Levels Affect Serum Phospholipids, Inflammation inT2D, CVD
- American College of Physicians Releases 4 Guidelines for HbA1c Targets in T2D
- Dyslipidemia Drug Indications
- No Difference in Weight Loss Outcomes With Low-Fat vs Low-Carbohydrate Diet
- Damaging Effects of Gastric Bypass Surgery on Bone Mass and Microarchitecture
- Gastric Bypass Surgery Linked to Increased Risk for Nonvertebral Fractures
- Common Plant-Derived Oils May Contain Endocrine-Disrupting Chemicals
- Red Meat Consumption Linked to Insulin Resistance and Steatohepatitis
- Effect of High Androgen Levels on Cardiovascular Risk in Postmenopausal Women
- Fertility in Women Negatively Affected by Asthma Medications
- Glucocorticoid Use in COPD Does Not Increase Fracture Risk